Emma Walmsley, GSK CEO
Updated: GSK unintimidated by RSV vaccine uptake challenges, Shingrix US sales drop
In the face of broader rollout challenges that could limit uptake of Arexvy, GSK said it is confident that sales for its blockbuster asset will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
